Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Excaliard raises $15.5 million, licenses antisense compounds

Excaliard (Encinitas, Calif.) raised $15.5 million in a series A round

Read the full 113 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE